APRICOXIB Cyclooxygenase-2 (COX-2) Inhibitor Oncolytic

被引：0
|
作者：
Edelman, Martin J. [1 ]
机构：
[1] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
来源：
DRUGS OF THE FUTURE | 2011年 / 36卷 / 07期
关键词：
CS-706; R-109339; TG-01; TP-1001; TP-2001; METASTATIC BREAST-CANCER; CELL LUNG-CANCER; DOUBLE-BLIND; CARDIOVASCULAR EVENTS; COVALENT BINDING; PHASE-II; CELECOXIB; EXPRESSION; ROFECOXIB; CS-706;
D O I：
10.1358/dof.2011.036.07.1608943
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Overexpression of cyclooxygenase-2 (COX-2) has been implicated as a tumor-initiating and -promoting event for a number of common solid tumors, including lung, breast and colon cancer. Considerable epidemiological evidence supports COX-2 inhibition as a method of chemoprevention. Inhibition of COX-2 in laboratory models has been demonstrated to be antineoplastic both by itself and in combination with cytotoxic and targeted agents. Apricoxib is a novel, potent and selective inhibitor of COX-2 currently under development as an anti-cancer agent, as well as an analgesic. This review discusses the pharmacology, preclinical and clinical results with apricoxib, focusing on its potential use in oncology.
引用
收藏
页码：503 / 509
页数：7
相关论文
共 50 条
  • [21] Effect of glycosylation of cyclooxygenase-2 (COX-2) on homodimerization
    Vann-Victorino, Daniel DeWayne Colbert
    Cunanan, Jelaine
    Chen, Mindy
    Chan, Rena
    Hall, Randall W.
    Sevigny, Mary B.
    FASEB JOURNAL, 2017, 31
  • [22] Expression of cyclooxygenase-2 (COX-2) in pituitary tumours
    Sokolowski, Grzegorz
    Baldys-Waligorska, Agata
    Trofimiuk, Malgorzata
    Adamek, Dariusz
    Hubalewska-Dydejczyk, Alicja
    Golkowski, Filip
    MEDICAL SCIENCE MONITOR, 2012, 18 (04): : CR252 - CR259
  • [23] Cyclooxygenase-2 (Cox-2) expression and angiogenesis in glioblastoma
    Onguru, Onder
    Gamsizkan, Mehmet
    Ulutin, Cuneyt
    Gunhan, Omer
    VIRCHOWS ARCHIV, 2007, 451 (02) : 238 - 238
  • [24] Cyclooxygenase-2 (COX-2) Activity is Regulated by Proteolysis
    Mancini, Arturo
    He, QingWen
    Di Battista, John A.
    INFLAMMATION RESEARCH, 2005, 54 : S120 - S120
  • [25] Isoorientin, a Selective Inhibitor of Cyclooxygenase-2 (COX-2) from the Tubers of Pueraria tuberosa
    Sumalatha, Manne
    Munikishore, Rachakunta
    Rammohan, Aluru
    Gunasekar, Duvvuru
    Kumar, Kotha Anil
    Reddy, Kakularam Kumar
    Azad, Rajaram
    Reddannaa, Pallu
    Bodo, Bernard
    NATURAL PRODUCT COMMUNICATIONS, 2015, 10 (10) : 1703 - 1704
  • [26] Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer γ-secretase modulators
    Narlawar, Rajeshwar
    Perez Revuelta, Blanca I.
    Haass, Christian
    Steiner, Harald
    Schmidt, Boris
    Baumann, Karlheinz
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (26) : 7588 - 7591
  • [27] Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH
    Wang, Jiping
    Cho, Nancy L.
    Zauber, Ann G.
    Hsu, Meier
    Dawson, Dawn
    Srivastava, Amitabh
    Mitchell-Richards, Kisha A.
    Markowitz, Sanford D.
    Bertagnolli, Monica M.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (07) : 728 - 736
  • [28] Celecoxib: A specific cyclooxygenase-2 (COX-2) inhibitor with antiangiogenic and anticancer activities.
    Masferrer, JL
    Leahy, K
    Zweifel, BS
    Moore, R
    Heuvelman, D
    Seibert, K
    Koki, AT
    CLINICAL CANCER RESEARCH, 2000, 6 : 4486S - 4486S
  • [29] Sweet's syndrome associated with the intake of a selective cyclooxygenase-2 (COX-2) inhibitor
    Rosmaninho, Aristoteles
    Lobo, Ines
    Selores, Manuela
    CUTANEOUS AND OCULAR TOXICOLOGY, 2011, 30 (04) : 298 - 301
  • [30] Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis
    Watson, DJ
    Harper, SE
    Zhao, PL
    Quan, H
    Bolognese, JA
    Simon, TJ
    ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (19) : 2998 - 3003
12345